CD38 and Miyoshi myopathy: These studies confirmed that the combination of anti-CD38 mAbs with conventional therapies dramatically improved the clinical outcome of MM patients (56–59).Thus, further studies aimed at the characterization of novel combined therapies that include anti-CD38 immune effectors might be pivotal to design effective clinical strategies to increase progression-free and overall survival of MM patients.